Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
Payam Tabarsi, Hossein Vahidi, Ali Saffaei, Seyed Mohammad, Reza Hashemian, Hamidreza Jammati, Bahram Daraei, Arash Mahboubi, Farzad Kobarfard, Majid Marjani, Afshin Moniri, Zahra Abtahian, Atefeh Abedini, Alireza Eslaminejad, Jalal Heshmatnia, Maryam Sadat Mirenayat, Atefeh Fakharian, Sharareh Seifi, Mohsen Sadeghi, Alireza Dastan, Sara Haseli, Seyed Alireza, Raha Eskandari, Sahar Yousefian, Mohammad Varahram, Alireza Za, Ali Akbar Velayati, Farzaneh Dastan
doi:10.22037/ijpr.2021.115510.15401
Coronavirus disease -19 (COVID-19) pandemic, caused by SARS-CoV-2, has gradually spread worldwide, becoming a major public health event. This situation requires designing a novel antiviral agent against the SARS-CoV-2; however, this is time-consuming and the use of repurposed medicines may be promising. One such medicine is favipiravir, primarily introduced as an anti-influenza agent in east world. The aim of this study was to evaluate the efficacy and safety of favipiravir in comparison with lopinavir-ritonavir in SARS-CoV-2 infection. In this randomized clinical trial, 62 patients were recruited. These patients had bilateral pulmonary infiltration with peripheral oxygen saturation lower than 93%. The median time from symptoms onset to intervention initiation was seven days. Favipiravir was not available in the Iranian pharmaceutical market, and it was decided to formulate it at the
References
Boretti, Favipiravir use for SARS CoV-2 infection, Pharmacol. Rep
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Coomes, Haghbayan, Favipiravir, an antiviral for COVID-19?, J. Antimicrob. Chemother
Dastan, Nadji, Saffaei, Tabarsi, Tocilizumab administration in a refractory case of COVID-19, Int. J. Antimicrob. Agents
Dastan, Tabarsi, Marjani, Moniri, Hashemian et al., Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces, Iran. J. Pharm. Res
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther
Gioia, Ciaccio, Simone, Fasciglione, Di Masi et al., Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches, Biochem. Pharmacol
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin. Infect. Dis
Jordan, Stevens, Deval, Nucleosides for the treatment of respiratory RNA virus infections, Antivir. Chem. Chemother
Joseph, Dibas, Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review, Expert Rev. Anti Infect. Ther
Lambert, Petteway, Mcdanal, Hart, Leary et al., Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells, Antimicrob. Agents Chemother
Pan, Ye, Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19), Radiology
Reddy, Lai, Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options, Chembiochem
Rosa, Santos, Clinical trials on drug repositioning for COVID-19 treatment, Rev. Panam. Salud. Publica
Takian, Raoofi, Kazempour-Ardebili, COVID-19 battle during the toughest sanctions against Iran, Lancet
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis
Vakili, Fathi, Pezeshgi, Mohamadkhani, Hajiesmaeili et al., Critical complications of COVID-19: A descriptive meta-analysis study, Rev. Cardiovasc. Med
